HEALTH ALERT

Wednesday, February 9, 2022

Outpatient Treatment for COVID-19

Key Messages and Action Steps

- There are four available outpatient treatments for COVID-19: Paxlovid (oral antiviral), sotrovimab (intravenous monoclonal antibody), remdesivir (intravenous antiviral), and molnupiravir (oral anti-viral).

- Clinicians should be aware of patient prioritization recommendations and ensure patients at highest risk of severe COVID-19 disease are aware of and have access to these therapies.

- Clinicians should educate high-risk patients to contact them immediately after testing positive for COVID-19, including on home tests, and should treat without requiring confirmatory in-clinic testing.

- Locations providing these therapeutics can be found on DPH’s COVID-19 Outpatient Therapy Locator and HHS’s COVID-19 Therapeutics Locator.

Overview of Outpatient Treatment for COVID-19

- Outpatient COVID-19 treatments are indicated for individuals with mild to moderate illness due to SARS-CoV-2 infection who are at high risk of developing severe disease. This includes all patients ages 65 and older and patients with certain underlying conditions.

- Sotrovimab is the only monoclonal antibody treatment effective against the Omicron variant. No other monoclonal antibody treatments should currently be used.

- The NIH COVID-19 Treatment Panel Guidelines Panel’s recommendations for therapeutic management of non-hospitalized adults with COVID-19 recommends the following order of preference for the available outpatient treatments:

<table>
<thead>
<tr>
<th>PATIENT DISPOSITION</th>
<th>PANEL’S RECOMMENDATIONS</th>
</tr>
</thead>
</table>
  | Does Not Require Hospitalization or Supplemental Oxygen | All patients should be offered symptomatic management (AIII).
  |                      | For patients who are at high risk of progressing to severe COVID-19 (Ia) treatments are listed in order of preference based on efficacy and convenience of use: |
  |                      | - Ribonavir-boosted ritonavir (Paxlovid) (Alla)
  |                      | - Sotrovimab (Alla)
  |                      | - Remdesivir (IIBa)
  |                      | - Molnupiravir (IIBa)

The Panel recommends against the use of dexamethasone or other systemic corticosteroids in the absence of another indication (AIII).

- For more information or to subscribe, visit WWW.COOKCOUNTYHAN.ORG

Download 3-page PDF

For providers serving communities of color and high-risk populations facing barriers to treatment:

Feb. 17, 2022
Noon to 1 p.m.

Outpatient COVID-19 Therapeutics
An update with focus on indications and access

Go here to participate:
https://bit.ly/3nGvFq